Immunogenic cell death (ICD) enhancers-Drugs that enhance the perception of ICD by dendritic cells.
T cells
apoptosis/autophagy
cancer
dendritic cells
signal transduction
tumor immunity
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
19 Aug 2023
19 Aug 2023
Historique:
revised:
06
08
2023
received:
17
07
2023
accepted:
07
08
2023
medline:
19
8
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
aheadofprint
Résumé
The search for immunostimulatory drugs applicable to cancer immunotherapy may profit from target-agnostic methods in which agents are screened for their functional impact on immune cells cultured in vitro without any preconceived idea on their mode of action. We have built a synthetic mini-immune system in which stressed and dying cancer cells (derived from standardized cell lines) are confronted with dendritic cells (DCs, derived from immortalized precursors) and CD8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ligue contre le cancer (équipe labellisée)
Organisme : Agence Nationale de la Recherche (ANR)-Projets blancs
Organisme : AMMICa US23/CNRS UMS3655
Organisme : Association pour la Recherche sur le Cancer (ARC)
Organisme : Cancéropôle Ile-de-France
Organisme : Fondation pour la Recherche Médicale (FRM)
Organisme : Elior; Equipex Onco-Pheno-Screen
Organisme : European Joint Programme on Rare Diseases (EJPRD)
Organisme : European Research Council Advanced Investigator Award
ID : ICDCancer, 101052444
Organisme : European Union Horizon 2020 Project Oncobiome, Prevalung
ID : 101095604
Organisme : European Union Horizon 2020 Project Crimson
ID : 101016923
Organisme : Institut National du Cancer (INCa)
Organisme : Institut Universitaire de France
Organisme : LabEx Immuno-Oncology
ID : ANR-18-IDEX-0001
Organisme : Cancer Research ASPIRE Award from the Mark Foundation
Organisme : RHU Immunolife; Seerave Foundation
Organisme : SIRIC Cancer Research and Personalized Medicine (CARPEM)
Informations de copyright
© 2023 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
Références
Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20(12):743-756.
Haerinck J, Goossens S, Berx G. The epithelial-mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat Rev Genet. 2023. doi: 10.1038/s41576-023-00601-0
Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652-1669.
Garbe C, Dummer R, Amaral T, et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023;29:1310-1312.
Lopez-Otin C, Kroemer G. Hallmarks of health. Cell. 2021;184(1):33-63.
Kroemer G, McQuade JL, Merad M, Andre F, Zitvogel L. Bodywide ecological interventions on cancer. Nat Med. 2023;29(1):59-74.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73.
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487-500.
Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691-1701.
de Mingo PA, Gardner A, Hiebler S, et al. TIM-3 regulates CD103(+) dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018;33(1):60-74.e6.
Ashour D, Arampatzi P, Pavlovic V, et al. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. JCI Insight. 2020;5(10):e135143.
Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678-1684.
Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638-652.
Stoll G, Iribarren K, Michels J, et al. Calreticulin expression: interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Onco Targets Ther. 2016;5(7):e1177692.
Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482-491.
Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14(10):1848-1850.
Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20(8):e452-e463.
Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062-1079.
Gomes-da-Silva LC, Zhao L, Bezu L, et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO J. 2018;37(13):e98354.
Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10(1):1486.
Petrazzuolo A, Perez-Lanzon M, Martins I, et al. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death Dis. 2021;12(8):713.
Angelova AL, Grekova SP, Heller A, et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol. 2014;88(10):5263-5276.
Kepp O, Marabelle A, Zitvogel L, Kroemer G. Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol. 2020;17(1):49-64.
Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920-928.
Liu P, Chen J, Zhao L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Onco Targets Ther. 2022;11(1):2093518.
Bloy N, Garcia P, Laumont CM, et al. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev. 2017;280(1):165-174.
Admon A. The biogenesis of the immunopeptidome. Semin Immunol. 2023;67:101766.
Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol. 2021;18(9):591-602.
Feng M, Marjon KD, Zhu F, et al. Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nat Commun. 2018;9(1):3194.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059.
Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301-1309.
Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972-978.
Kepp O, Loos F, Liu P, Kroemer G. Extracellular nucleosides and nucleotides as immunomodulators. Immunol Rev. 2017;280(1):83-92.
Roussot N, Ghiringhelli F, Rebe C. Tumor immunogenic cell death as a mediator of intratumor CD8 T-cell recruitment. Cell. 2022;11(22):3672.
Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Onco Targets Ther. 2014;3(9):e955691.
Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337.
Le Naour J, Liu P, Zhao L, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11(2):408-423.
Zhao L, Liu P, Xie W, et al. A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. STAR Protoc. 2021;2(3):100732.
Xie W, Forveille S, Iribarren K, et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Onco Targets Ther. 2019;8(11):e1656502.
Kepp O, Zitvogel L, Kroemer G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Onco Targets Ther. 2020;9(1):1795995.
Montes de Oca R, Alavi AS, Vitali N, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941-1955.
Lassiter G, Bergeron C, Guedry R, et al. Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 2021;28(1):640-660.
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29(5):347-364.
Henson PM. Cell removal: efferocytosis. Annu Rev Cell Dev Biol. 2017;33:127-144.
Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21(1):79-91.
Humeau J, Leduc M, Cerrato G, Loos F, Kepp O, Kroemer G. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) in autophagy. Cell Death Dis. 2020;11(6):433.
Bezu L, Sauvat A, Humeau J, et al. eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25(8):1375-1393.
Liu P, Zhao L, Loos F, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell. 2020;77(4):748-760.e9.
Humeau J, Sauvat A, Cerrato G, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med. 2020;12(5):e11622.
Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science. 2015;350(6258):328-334.
Wang Z, Chen J, Hu J, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019;129(11):4850-4862.
Kepp O, Chen G, Carmona-Gutierrez D, Madeo F, Kroemer G. A discovery platform for the identification of caloric restriction mimetics with broad health-improving effects. Autophagy. 2020;16(1):188-189.
Liu P, Zhao L, Kepp O, Kroemer G. Quantitation of calreticulin exposure associated with immunogenic cell death. Methods Enzymol. 2020;632:1-13.
Martins I, Kepp O, Menger L, et al. Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol. 2013;1004:43-56.
Forveille S, Sauvat A, Zhang S, Zhao L, Kroemer G, Kepp O. Assessment of type I interferon responses as a feature of immunogenic cell death. Methods Cell Biol. 2022;172:135-143.
Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
Yang Z, Gao D, Zhao J, et al. Thermal immuno-nanomedicine in cancer. Nat Rev Clin Oncol. 2023;20(2):116-134.
Zhang Q, Wu P, Wu J, et al. Chemoimmunological cascade cancer therapy using fluorine assembly nanomedicine. ACS Nano. 2023;17(8):7498-7510.
Ren E, Wang Y, Liang T, et al. Local drug delivery techniques for triggering immunogenic cell death. Small Methods. 2023;e2300347. doi: 10.1002/smtd.202300347
Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128-1138.
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571-1580.
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40.
Kalanxhi E, Meltzer S, Schou JV, et al. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018;118(10):1322-1328.
Pol JG, Le Naour J, Kroemer G. FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin. Onco Targets Ther. 2020;9(1):1755214.
Tsutsumi H, Inoue H, Shiraishi Y, et al. Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors. Lung Cancer. 2023;181:107264.
Wemeau M, Kepp O, Tesniere A, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104.
Fucikova J, Truxova I, Hensler M, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016;128(26):3113-3124.
Kasikova L, Hensler M, Truxova I, et al. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J Immunother Cancer. 2019;7(1):312.
Menger L, Vacchelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012;4(143):143ra199.
Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369-383.
Rossevold AH, Andresen NK, Bjerre CA, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573-2583.
Egelston CA, Guo W, Yost SE, et al. Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunol Immunother. 2023;72:3013-3027.
Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645-654.
Boni V, Pistilli B, Brana I, et al. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 2022;7(5):100571.
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221.
Zhou H, Forveille S, Sauvat A, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016;7(3):e2134.
Yamazaki T, Pitt JM, Vetizou M, et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 2016;23(6):1004-1015.
Yamazaki T, Buque A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Onco Targets Ther. 2020;9(1):1721810.
Karp DD, Camidge DR, Infante JR, et al. Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 2022;49:101430.
Ahrens S, Zelenay S, Sancho D, et al. F-Actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36(4):635-645.
Canton J, Blees H, Henry CM, et al. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat Immunol. 2021;22(2):140-153.
Yang M, Li C, Zhu S, et al. TFAM is a novel mediator of immunogenic cancer cell death. Onco Targets Ther. 2018;7(6):e1431086.
Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725-741.
Sauvat A, Cerrato G, Humeau J, Leduc M, Kepp O, Kroemer G. High-throughput label-free detection of DNA-to-RNA transcription inhibition using brightfield microscopy and deep neural networks. Comput Biol Med. 2021;133:104371.
Zhang S, Zhao L, Guo M, et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer. 2023;11(7):e006785.
Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100(6):655-669.
Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984;28(1):38-61.
Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W, Pardo LA. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol. 2004;124(4):301-317.
Li H, Xiao Y, Li Q, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40(1):36-52.e9.
Verdoodt F, Dehlendorff C, Jaattela M, et al. Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay. J Natl Cancer Inst. 2020;112(9):964-967.
Ellegaard AM, Dehlendorff C, Vind AC, et al. Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine. 2016;9:130-139.
Mallardo D, Simeone E, Vanella V, et al. Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization. J Transl Med. 2022;20(1):436.
Chiang CH, Chiang CH, Peng CY, et al. Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors. Eur J Cancer. 2022;174:1-9.
Carbonnier V, Le Naour J, Bachelot T, et al. Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer. Onco Targets Ther. 2023;12(1):2189823.
Buque A, Bloy N, Perez-Lanzon M, et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat Commun. 2020;11(1):3819.
Thierry S, Maadadi S, Berton A, et al. TL-532, a novel specific toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization. Microb Cell. 2023;10(6):117-132.
Le Naour J, Thierry S, Scuderi SA, et al. A chemically defined TLR3 agonist with anticancer activity. Onco Targets Ther. 2023;12(1):2227510.
Elkin SR, Oswald NW, Reed DK, Mettlen M, MacMillan JB, Schmid SL. Ikarugamycin: a natural product inhibitor of clathrin-mediated endocytosis. Traffic. 2016;17(10):1139-1149.
Wang C, Niederstrasser H, Douglas PM, et al. Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun. 2017;8(1):2270.
Jiang SH, Dong FY, Da LT, et al. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. FASEB J. 2020;34(3):3943-3955.
Wang Z, Xu F, Hu J, et al. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. J Immunother Cancer. 2021;9(5):e002155.
Lee J, Bogyo M. Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol. 2013;17(1):118-126.
Kumar SA, Ananda Kumar TD, Beeraka NM, et al. Machine learning and deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry. Future Med Chem. 2022;14(4):245-270.
Dong ZC, Wang Y, Yang F, Wan F. A brief introduction to chemical proteomics for target deconvolution. Eur Rev Med Pharmacol Sci. 2022;26(17):6014-6026.
Melssen MM, Petroni GR, Chianese-Bullock KA, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. J Immunother Cancer. 2019;7(1):163.
Pavlick A, Blazquez AB, Meseck M, et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol Res. 2020;8(1):70-80.
Bhardwaj N, Friedlander PA, Pavlick AC, et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2020;1(12):1204-1217.
Ogino H, Taylor JW, Nejo T, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022;132(3):e151239.
Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautes-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441-457.
Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011;71(14):4809-4820.
Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61.
Sukkurwala AQ, Adjemian S, Senovilla L, et al. Screening of novel immunogenic cell death inducers within the NCI mechanistic diversity set. Onco Targets Ther. 2014;3:e28473.
Xie W, Mondragon L, Mauseth B, et al. Tumor lysis with LTX-401 creates anticancer immunity. Onco Targets Ther. 2019;8(7):1594555.
Zhou H, Mondragon L, Xie W, et al. Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death Dis. 2018;9(11):1086.
Liu P, Zhao L, Loos F, et al. Identification of pharmacological agents that induce HMGB1 release. Sci Rep. 2017;7(1):14915.
Liu P, Zhao L, Kepp O, Kroemer G. Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death. Onco Targets Ther. 2019;8(7):1596652.
Petrazzuolo A, Perez-Lanzon M, Liu P, Maiuri MC, Kroemer G. Crizotinib and ceritinib trigger immunogenic cell death via on-target effects. Onco Targets Ther. 2021;10(1):1973197.
Wang Y, Xie W, Humeau J, et al. Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy. J Immunother Cancer. 2020;8(1):e000462.
Wu Q, Tian AL, Li B, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Cancer. 2021;9(6):e002722.
Wu Q, Tian AL, Durand S, et al. Isobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy. Cell Death Dis. 2020;11(11):1015.
Humeau J, Sauvat A, Kepp O, Kroemer G. An unexpected link between immunogenic cell death and inhibition of gene transcription. Onco Targets Ther. 2020;9(1):1792039.